Pharmaceutical Technology, Dec 2, 2009 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Dec 2, 2009
Online Exclusives
Bringing a Science-Based Approach to Regulation: The Story of the Product Quality Research Institute
By Gordon Hansen , Chris Allen
The authors describe the development and organization of the Product Quality Research Institute and highlight some of the important projects conducted by its Working Groups.
Polymorph Screening Strategies: A Q&A with Jan-Olav Henck
By Patricia Van Arnum
Polymorph screening is a critical step in developing an active pharmaceutical ingredient for a pharmaceutical formulation.
The Path to Product Stability Is through Water
By Harry G. Brittain, PhD
Readers can learn about the importance of measuring and controlling water activity in a comprehensive new book.
Special Report
Headed Up or Down? Pharma's Position in the Current Economy
By Michelle Hoffman
Results from our annual employment survey.
Ingredients Insider
Solid-State Chemistry: A Technical Forum
By Patricia Van Arnum
Leading experts share insight on polymorphism and crystallization.
Peer-Reviewed Research
Moisture-Activated Dry Granulation Part II: The Effects of Formulation Ingredients and Manufacturing-Process Variables on Granulation Quality Attributes
By Ismat Ullah , Jennifer Wang , Shih-Ying Chang , Hang Guo , San Kiang , Nemichand B. Jain
In this article, the authors evaluated the effects of the granulating binder level, binder type, water amount, and water-droplet size on the MADG process.
Using Polyethyline Oxide Blends to Assess the Effect of Excipient Variability
By Jennifer L'Hote Gaston , Robert Schmitt , Cheryl Karas , Youngfu Li
The authors discuss a study that demonstrates the use of polyethylene oxide mixtures to investigate the effect of polymer viscosity on formulation robustness.
From The Editor
An FDA Seal of Approval for Online Information?
By Michelle Hoffman
With so many healthcare and pharmacy websites, consumers could use the agency's nod of support.
PharmTech Talk
One Voice; Many Possibilities
By Patricia Van Arnum
Particularly in a more connected world, individual contributions can make a difference.
Agent-In-Place
Setting Things Straight
By Control, a senior compliance officer
Blame it on cafeteria gossip, outdated procedures, and major miscommunication.
In the Spotlight
In the Spotlight
Editors' Picks of Pharmaceutical Science & Technology Innovations
News
In the Field: Report from India
By A. Nair
Multinational firms and governments around the world are flocking to India for R&D partnerships.
Washington Report
Generic Drugs Come of Age
By Jill Wechsler
Generic-drug manufacturers look to expand into biologics and complex dosage forms. This article contains bonus online-exclusive material.
Inside PIC/S
Inside PIC/S: Implementing Quality Risk Management
By Lionel Viornery , Philippe Legoff
Representatives to the PIC/S provide an example of methodology for implementing ICH Q9.
Outsourcing Outlook
Squeezed for Cash
By Jim Miller
Big Pharma's efforts to reduce working capital will hurt CMOs for years to come.
Viewpoint
Can We Save the Technical Conference?
By Lynn D. Torbeck
Dumbed-down presentations and poor speaker selections are destroying a valuable industry tool.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here